Edgewise Therapeutics reports positive updates from HCM drug EDG-7500
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The product will be launched in Q1FY26
Subscribe To Our Newsletter & Stay Updated